Nutraceuticals:  

Nutraceuticals to Reduce the Driving Forces of Chronic Pain (Part 1)

This section (Part 1) presents a synthesis of research to identify the nutraceuticals with the best evidence of efficacy for the following conditions that are driving forcex in the development and maintenance of chronic pain:

See: 

See also: 

Nutraceutical Patient Guides:

      Nutraceuticals (Part 1):

  1. Acetyl-L-Carnitine (ALC) for Chronic Pain: A Patient Guide
  2. Alpha-Lipoic Acid (ALA) for Chronic Pain: A Patient Guide
  3. Boswellia for Chronic Pain: A Patient Guide
  4. CoQ10 for Chronic Pain: A Patient Guide
  5. Curcumin for Chronic Pain: A Patient Guide
  6. Magnesium for Chronic Pain: A Patient Guide
  7. N-Acetylcysteine (NAC) for Chronic Pain: A Patient Guide
  8. Omega-3 Fatty Acids for Chronic Pain: A Patient Guide
  9. Palmitoylethanolamide (PEA) for Chronic Pain- A Patient Guide
  10. Resveratrol for Chronic Pain: A Patient Guide

 

      Nutraceutical Patient Guides:

      Nutraceuticals (Part 2):

  1. Melatonin for Chronic Pain: A Patient Guide
  2. Nicotinamide Riboside (NAD+ Precursors) for Chronic Pain
  3. Quercetin for Chronic Pain: A Patient Guide
  4. Sulforaphane (SFN) for Chronic Pain: A Patient Guide
  5. Taurine for Chronic Pain: A Patient Guide
  6. Vitamin D for Chronic Pain: A Patient Guide

 

 

Key to Links:

  • Grey text – handout
  • Red text – another page on this website
  • Blue text – Journal publication

Definitions and Terms Related to Pain

 

  Links to Nutraceuticals on this page (Part 1):

  1. Acetyl-L-Carnitine (ALC) 
  2. Alpha-Lipoic Acid (ALA) 
  3. Boswellia
  4. CoQ10
  5. Curcumin
  6. Magnesium
  7. N-Acetylcysteine (NAC)
  8. Omega-3 Fatty Acids
  9. Palmitoylethanolamide (PEA) 
  10. Resveratrol

SUMMARY AND INTEGRATION

 

—

Nutraceuticals to Reduce the Driving Forces of Chronic Pain

PART 1 (#1-10)

Summary

Updated: March 2026

This comprehensive treatise synthesizes current evidence for nutraceutical interventions targeting the pathophysiological mechanisms underlying chronic pain, including systemic inflammation, oxidative stress, neuroinflammation and mitochondrial dysfunction as well as entral sensitization,.

The following analysis evaluates the highest-quality current evidence for each compound, including recommendations for integrating these agents into multimodal pain management strategies.

—

1. ACETYL-L-CARNITINE (ALC)

   Level of Evidence

      Grade B-C: Cochrane review, multiple RCTs; moderate-quality evidence with some inconsistency

   Primary Indications

  1. Diabetic peripheral neuropathy (strongest evidence)
  2. HIV/antiretroviral-induced neuropathy
  3. Chemotherapy-induced peripheral neuropathy
  4. Compression neuropathies
  5. Fibromyalgia (emerging evidence)

   Mechanisms of Action

  1. Epigenetic modulation: Acetylates NF-κB p65/RelA, enhancing transcription of GRM2 gene encoding mGlu2 receptors, inducing long-term upregulation with sustained analgesic effects
  2. Neurotrophic effects: Promotes nerve growth factor (NGF) expression and peripheral nerve regeneration
  3. Mitochondrial function: Essential for fatty acid transport into mitochondria for β-oxidation; enhances ATP production
  4. Neurotransmitter modulation: Provides acetyl groups for acetylcholine synthesis; modulates serotonin and dopamine
  5. Antioxidant activity: Protects against oxidative stress-induced neuronal damage

   Recommended Dosing

  • Standard dose: 1500-3000 mg/day in divided doses (500-1000 mg TID)
  • Diabetic neuropathy: 2000-3000 mg/day (doses >1500 mg/day more effective)
  • Duration: Minimum 6-12 months for full therapeutic effect
  • Route: Oral preferred; IM-oral sequential regimens studied

   Formulation Considerations

  • Acetyl-L-carnitine preferred over L-carnitine for CNS penetration
  • Take on empty stomach for optimal absorption

   Estimated Cost

  • Standard ALC (1500-3000 mg/day): $25-50/month

   Safety Profile – Good tolerability

  • Mild GI upset (nausea, vomiting) uncommon
  • Headache, paresthesia reported rarely
  • No serious adverse events in clinical trials
  • Theoretical concern: may increase seizure risk in susceptible individuals

   Synergistic Combinations

  1. Alpha-lipoic acid: Complementary mitochondrial and neurotrophic effects
  2. B-complex vitamins: Enhanced nerve regeneration
  3. Omega-3 fatty acids: Additive anti-inflammatory effects

   Clinical Pearls

  • Unique property: Analgesia outlasts treatment duration due to epigenetic mechanisms (effects persist 2-5 weeks after discontinuation).
  • Dose-dependent response; higher doses (>1500 mg/day) more effective
  • Cochrane review notes “very uncertain” evidence for pain reduction in diabetic neuropathy; larger trials needed
  • May be more effective in diabetic than non-diabetic neuropathy

2. ALPHA-LIPOIC ACID (ALA)

   Level of Evidence

      Grade A-B: Cochrane review, multiple systematic reviews and meta-analyses, numerous RCTs; moderate-to-high quality evidence

   Primary Indications

  1. Primary: Diabetic peripheral neuropathy (strongest evidence)
  2. Burning mouth syndrome
  3. Carpal tunnel syndrome
  4. Complex regional pain syndrome type I
  5. Chemotherapy-induced peripheral neuropathy
  6. Headache/migraine

   Mechanisms of Action

  1. Antioxidant activity: Direct free radical scavenging; regenerates vitamins C and E, glutathione
  2. Mitochondrial function: Essential cofactor in oxidative metabolism; enhances ATP production
  3. Neuroinflammation reduction: Decreases microglial activation, astrocyte reactivity, and pro-inflammatory cytokine release
  4. NMDA receptor modulation: Reduces central sensitization
  5. Microcirculation improvement: Enhances endoneurial blood flow in diabetic neuropathy
  6. Nrf2 activation: Upregulates endogenous antioxidant systems

   Recommended Dosing

  • Diabetic neuropathy: 600 mg/day oral (most studied dose)
  • Alternative regimens: 1200 mg/day or 1800 mg/day (dose-dependent response for symptom reduction)
  • IV loading: 600 mg IV daily × 2-3 weeks, then 600 mg oral daily
  • Other neuropathies: 600-1200 mg/day oral
  • CRPS-I: 100 mg/kg/day (approximately 600-800 mg for average adult)
  • Timing: Take on empty stomach (30-60 minutes before meals) for optimal absorption
  • Duration: Minimum 6 months; benefits plateau at 12-24 months

   Formulation Considerations

  • R-alpha-lipoic acid (R-ALA): More bioavailable than racemic mixture
  • Sustained-release formulations: May improve tolerability
  • Both IV and oral routes effective; oral preferred for long-term management

   Estimated Cost

  • Standard ALA (600 mg/day): $20-35/month
  • R-ALA formulations: $35-60/month

   Safety Profile – Very good safety

  • Well-tolerated at doses up to 1800 mg/day
  • Mild GI upset (nausea, vomiting) at doses >1000 mg/day (uncommon)
  • Rare: skin rash, headache
  • No serious adverse events in clinical trials
  • Theoretical hypoglycemia risk in diabetics; monitor glucose

   Contraindications/Precautions

  • Use caution in patients with diabetes (may enhance insulin sensitivity)
  • Theoretical interaction with chemotherapy (antioxidant interference); timing considerations needed

   Synergistic Combinations

  1. Acetyl-L-carnitine: Complementary mitochondrial and neurotrophic effects
  2. B-complex vitamins: Enhanced nerve regeneration
  3. Omega-3 fatty acids: Additive anti-inflammatory effects
  4. Curcumin: Synergistic antioxidant and anti-inflammatory mechanisms

   Clinical Pearls

  • Strongest evidence for diabetic neuropathy; Cochrane review shows probable modest benefit
  • Dose-dependent response for symptom reduction (TSS)
  • May reduce need for analgesics in diabetic neuropathy.
  • IV loading followed by oral maintenance may provide faster onset
  • Effects on pain more consistent than effects on nerve conduction studies

3. BOSWELLIA SERRATA

   Level of Evidence

      Grade A-B: Multiple systematic reviews and meta-analyses, numerous RCTs; moderate-to-high quality evidence for osteoarthritis

   Primary Indications

  1. Osteoarthritis (strongest evidence)
  2. Rheumatoid arthritis
  3. Inflammatory joint pain
  4. Low back pain
  5. Inflammatory bowel disease-associated pain

   Mechanisms of Action

  • 5-LOX inhibition: Boswellic acids (particularly AKBA) inhibit 5-lipoxygenase, reducing leukotriene synthesis
  • COX-2 inhibition: Complementary inhibition of prostaglandin synthesis
  • NF-κB suppression: Reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
  • MMP inhibition: Protects cartilage matrix from degradation
  • Anti-inflammatory cytokine reduction: Decreases hs-CRP and inflammatory markers

   Recommended Dosing

  • Osteoarthritis: 100-400 mg/day of standardized extract (30% AKBA)
  • Standard Boswellia extract: 300-500 mg three times daily
  • Enriched extracts (standardized to AKBA): 100-250 mg twice daily
  • Duration: Minimum 4 weeks; optimal effects at 8-12 weeks
  • Improvements may be seen as early as 5 days with standardized extracts

   Formulation Considerations

  • Standardized extracts (30% 3-acetyl-11-keto-β-boswellic acid/AKBA) preferred
  • Enriched Boswellia extracts show superior efficacy
  • Combination with non-volatile oil may enhance absorption

   Estimated Cost

  • Standard Boswellia extract: $15-30/month
  • Standardized/enriched extracts: $25-50/month

   Safety Profile – Excellent safety

  • Well-tolerated in clinical trials
  • Mild GI upset (rare)
  • No serious adverse events reported
  • May actually reduce adverse events compared to placebo in some studies

Synergistic Combinations

  1. Curcumin: Additive COX-2 and 5-LOX inhibition
  2. Omega-3 fatty acids: Complementary anti-inflammatory pathways
  3. Glucosamine/chondroitin: Enhanced joint protection
  4. Celery seed extract: Synergistic anti-inflammatory effects

Clinical Pearls

  • Cochrane review provides high-quality evidence for enriched Boswellia extract (100 mg) improving OA symptoms
  • Meta-analysis shows significant improvements in VAS pain, WOMAC scores, and Lequesne index
  • Rapid onset of action possible with standardized extracts (within 5 days).
  • Reduces inflammatory biomarkers (TNF-α, hs-CRP, IL-6)
  • Recommended treatment duration at least 4 weeks

4. COENZYME Q10 (CoQ10/Ubiquinol)

   Level of Evidence

     Grade B: Multiple RCTs in fibromyalgia; moderate-quality evidence

   Primary Indications

  1. Primary: Fibromyalgia (strongest evidence)
  2. Chronic fatigue syndrome/ME/CFS
  3. Post-viral fatigue syndromes (including long COVID)
  4. Mitochondrial Dysfunction-associated pain
  5. Migraine prophylaxis
  6. Statin-induced myalgia

   Mechanisms of Action

  • Mitochondrial electron transport: Essential cofactor in oxidative phosphorylation; enhances ATP production
  • Antioxidant activity: Membrane-bound antioxidant; reduces lipid peroxidation
  • Anti-inflammatory effects: Reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
  • AMPK activation: Improves cellular energy sensing and metabolic regulation
  • Mitochondrial biogenesis: Upregulates PGC-1α and mitochondrial DNA copy number
  • Neuroinflammation reduction: Decreases microglial activation and oxidative stress in CNS

   Recommended Dosing

  • Fibromyalgia: 300 mg/day (most studied dose)
  • As adjunct to pregabalin: 200-300 mg/day
  • Chronic fatigue syndrome/ME/CFS: 200 mg/day (often combined with NADH 20 mg/day)
  • Migraine prophylaxis: 300 mg/day (100 mg three times daily)
  • Statin-induced myalgia: 100-400 mg/day
  • Mitochondrial disorders: 100-600 mg/day
  • Timing: Take with meals containing fat to enhance absorption
  • Duration: Minimum 8-12 weeks for fibromyalgia; 3 months for migraine prophylaxis

   Formulation Considerations

  • Ubiquinol (reduced form): Better absorbed than ubiquinone, especially in older adults
  • Softgel formulations with oil base improve absorption
  • Divided dosing may improve tolerability

   Estimated Cost

  • Standard CoQ10 (ubiquinone): $20-40/month
  • Ubiquinol formulations: $35-60/month

   Safety Profile – Excellent safety

  1. Well-tolerated at doses up to 1200 mg/day
  2. Mild GI upset (rare)
  3. May reduce warfarin efficacy (monitor INR)
  4. No serious adverse events in clinical trials

   Synergistic Combinations

  1. NADH: Enhanced mitochondrial function (particularly for CFS)
  2. Alpha-lipoic acid: Complementary antioxidant effects
  3. Magnesium: Improved mitochondrial function
  4. PQQ: Enhanced mitochondrial biogenesis

Clinical Pearls

  • Improves clinical symptoms and pathologic alterations in fibromyalgia
  • Reduces brain activity and mitochondrial dysfunction in pregabalin-treated fibromyalgia patients
  • Higher doses and longer duration correlate with greater benefit (dose-dependent effect).
  • Effects may continue after discontinuation
  • Consider in patients with statin-induced myalgia or mitochondrial dysfunction

5. CURCUMIN (Turmeric Extract)

   Level of Evidence

      Grade A-B: Multiple systematic reviews and meta-analyses, numerous RCTs; moderate-to-high quality evidence

   Primary Indications

  1. Neuropathic pain (all etiologies)
  2. Osteoarthritis
  3. Inflammatory pain syndromes
  4. Central sensitization states
  5. Neuroinflammation-driven chronic pain

   Mechanisms of Action

  • Neuroinflammation suppression: Inhibits NALP1 and NLRP3 inflammasome activation in spinal astrocytes and microglia
  • Microglial modulation: Promotes M2 (anti-inflammatory) polarization while suppressing M1 (pro-inflammatory) phenotype
  • Signaling pathway inhibition: Blocks JAK2-STAT3 and NF-κB cascades, reducing IL-1β, IL-6, and TNF-α production
  • Autophagy induction: Enhances cellular clearance mechanisms to reduce inflammasome activation
  • Central sensitization attenuation: Reduces spinal cord hyperexcitability and wind-up phenomena

   Recommended Dosing

  • Standard formulation: 500-1000 mg twice daily (total 1000-2000 mg/day)
  • Enhanced bioavailability formulations (with piperine, liposomal, or nano-curcumin): 250-500 mg twice daily
  • Optimal range for analgesia: 100-250 mg/kg in preclinical models translates to approximately 1000-2000 mg/day in humans
  • Route: Oral administration preferred
  • Duration: Minimum 8-12 weeks for full therapeutic effect; benefits may appear within 4 weeks

   Formulation Considerations

  • Phytosomal curcumin recommended
  • Nano-curcumin demonstrates superior efficacy compared to standard curcumin
  • Enhanced bioavailability formulations strongly recommended due to curcumin’s poor native absorption

   Estimated Cost

  • Standard curcumin: $15-30/month
  • Enhanced bioavailability formulations: $30-60/month
  • Nano-curcumin: $40-80/month

   Safety Profile – Excellent tolerability

  • No serious adverse events reported in clinical trials
  • Mild gastrointestinal upset at doses >2000 mg/day (rare)
  • No significant drug interactions reported
  • Safe for long-term use (>12 months studied)

   Synergistic Combinations

  1. Omega-3 fatty acids: Complementary anti-inflammatory mechanisms
  2. Boswellia serrata: Additive COX-2 and 5-LOX inhibition
  3. Palmitoylethanolamide (PEA): Enhanced endocannabinoid modulation
  4. Alpha-lipoic acid: Synergistic antioxidant and anti-inflammatory effects

   Clinical Pearls

  • Most effective for neuropathic pain with neuroinflammatory component.
  • Dose-dependent response; higher doses (within safe range) more effective
  • Enhanced formulations essential for clinical efficacy
  • May reduce opioid requirements in chronic pain patients

—

6. MAGNESIUM

   Level of Evidence

      Grade B-C: Multiple RCTs with heterogeneous results; moderate-quality evidence for migraine, limited evidence for other pain conditions

   Primary Indications

  1. Migraine prophylaxis (strongest evidence)
  2. Fibromyalgia (emerging evidence)
  3. Neuropathic pain
  4. Complex regional pain syndrome
  5. Low back pain with neuropathic component

   Mechanisms of Action

  1. NMDA receptor antagonism: Physiological blocker of NMDA receptor ion channel; reduces central sensitization
  2. Calcium channel blockade: Modulates neuronal excitability
  3. Potassium channel modulation: Stabilizes neuronal membranes
  4. Nitric oxide pathway: May contribute to antinociceptive effects in somatic inflammatory pain
  5. Neuromuscular function: Essential for muscle relaxation and reducing muscle spasm

   Recommended Dosing (Elemental Mg)

  • Migraine prophylaxis: 400-600 mg/day oral (magnesium oxide, citrate, or dicitrate)
  • Fibromyalgia: 300-600 mg/day
  • General chronic pain: 200-400 mg/day
  • Duration: Minimum 12 weeks for migraine prophylaxis
  • Timing: Can be divided into 2-3 doses daily; evening dosing may improve sleep

   Formulation Considerations

  • Magnesium citrate and glycinate: Better absorbed than oxide
  • Magnesium dicitrate (600 mg): Studied for migraine prophylaxis
  • Avoid magnesium oxide if GI tolerability is an issue

   Estimated Cost

  • Standard magnesium supplements: $10-25/month

   Safety Profile – Good safety in patients with normal kidney function

  • GI intolerance (diarrhea, cramping) most common side effect
  • Toxicity associated with doses >5000 mg/day: hypotension, ileus, muscle weakness, lethargy
  • Risk of adverse events increased with reduced kidney function
  • Contraindicated in severe kidney impairment

   Synergistic Combinations

  • Riboflavin (B2): Complementary migraine prophylaxis
  • CoQ10: Enhanced mitochondrial function
  • Vitamin D: Improved absorption and utilization

   Clinical Pearls

  • VA/DoD guidelines provide “weak for” recommendation for migraine prophylaxis
  • Systematic review provides Grade C (possibly effective) evidence for migraine prevention
  • Lower serum magnesium levels associated with poorer sleep quality, higher pain severity, and greater functional impairment in fibromyalgia.
  • Evidence for chronic pain management remains equivocal; larger trials needed
  • Consider checking serum magnesium levels before supplementation

7. N-ACETYL CYSTEINE (NAC)

   Level of Evidence

      Grade B-C: Limited RCTs with mixed results; moderate-quality preclinical evidence, emerging clinical evidence

   Primary Indications

  1. Neuropathic pain (emerging evidence)
  2. Complex regional pain syndrome
  3. Chronic inflammatory pain
  4. Sickle cell disease -related pain
  5. Fibromyalgia (theoretical)

   Mechanisms of Action

  • mGlu2 receptor activation: Activates glial glutamate:cystine membrane exchanger (System xc-), enhancing endogenous activation of type-2 metabotropic glutamate receptors
  • MMP inhibition: Suppresses matrix metalloproteinase-9/2 activity, reducing neuroinflammation
  • Glutathione precursor: Enhances endogenous antioxidant capacity
  • IL-1β maturation blockade: Inhibits critical inflammatory substrate of MMPs
  • Microglial modulation: Inhibits CCI-induced microglia activation
  • NMDA receptor modulation: Reduces central sensitization

   Recommended Dosing

  • Chronic pain: 600-1200 mg twice daily (1200-2400 mg/day total)
  • Neuropathic pain: 1200-1800 mg/day
  • Duration: Minimum 8-12 weeks
  • Timing: Can be taken with or without food

   Formulation Considerations

  • Standard NAC capsules widely available
  • Effervescent formulations may improve tolerability
  • N-acetyl cysteine amide (NACA) has better CNS penetration (investigational)

   Estimated Cost

  • Standard NAC: $15-30/month

   Safety Profile – Good safety (well-established from mucolytic use)

  • GI upset (nausea, vomiting) most common
  • Sulfurous odor/taste
  • Rare: headache, rash
  • Extensively studied for acetaminophen overdose with excellent safety profile

   Synergistic Combinations

  1. Alpha-lipoic acid: Complementary antioxidant effects
  2. Omega-3 fatty acids: Additive anti-inflammatory mechanisms
  3. Topical meldonium: Enhanced NO-mediated tissue oxygenation for CRPS

   Clinical Pearls

  • Systematic review found insufficient evidence for definitive recommendations in chronic pain
  • Preclinical evidence shows potent analgesic effects via mGlu2 receptor activation
  • Human study demonstrated inhibition of nociceptive transmission (reduced laser-evoked potentials).
  • Unique mechanism: reinforces endogenous pain modulation rather than direct receptor agonism
  • May be more effective in inflammatory pain than neuropathic pain (tolerance develops in CCI model)
  • Further research warranted for CIPN

—

8. OMEGA-3 FATTY ACIDS (EPA/DHA)

   Level of Evidence

      Grade A: Multiple systematic reviews, meta-analyses, and large RCTs; high-quality evidence

   Primary Indications

  1. Chronic inflammatory pain
  2. Neuropathic pain (diabetic and non-diabetic)
  3. Fibromyalgia and central sensitization syndromes
  4. Rheumatoid arthritis
  5. Migraine prophylaxis
  6. Temporomandibular disorders
  7. Low back pain with neuropathic component

   Mechanisms of Action

  1. Specialized pro-resolving mediator (SPM) synthesis: Precursors for resolvins, maresins, and protectins
  2. Central sensitization modulation: Downregulates TRPV1 expression in pain-processing brain regions (thalamus, mPFC, SSC, ACC)
  3. Neuroinflammation reduction: Decreases pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
  4. Nociceptor modulation: Alters peripheral and central pain signaling independent of inflammation
  5. Membrane stabilization: Improves neuronal membrane fluidity and receptor function

   Recommended Dosing

  • Optimal dose: ≤1.35 g/day combined EPA+DHA (more effective than higher doses)
  • EPA-rich formulations: 1000-1500 mg EPA + 500-750 mg DHA daily
  • Ratio: EPA:DHA of 2:1 to 3:1 preferred for pain management
  • Duration: Minimum 6 months for maximal benefit; effects observable at 1 month, improving to 6 months
  • Timing: Can be taken with meals to enhance absorption and reduce GI effects

   Formulation Considerations

  1. Triglyceride form preferred over ethyl ester for better absorption
  2. Enteric-coated formulations reduce fishy aftertaste and GI upset
  3. Pharmaceutical-grade (molecularly distilled) to minimize contaminants

   Estimated Cost

  • Pharmaceutical-grade omega-3: $20-40/month
  • Prescription omega-3 (Lovaza, Vascepa): $50-200/month (insurance-dependent)

   Safety Profile – Excellent safety

  • Well-tolerated at therapeutic doses
  • Mild GI upset (fishy burps, loose stools) in 10% of patients
  • Theoretical bleeding risk at very high doses (>3 g/day); minimal at recommended doses
  • Monitor in patients on anticoagulation (generally safe with dose adjustment)
  • No significant adverse events in chronic pain trials

   Synergistic Combinations

  1. Curcumin: Complementary anti-inflammatory pathways
  2. Vitamin D: Enhanced immunomodulation
  3. Resveratrol: Synergistic mitochondrial and anti-inflammatory effects
  4. PEA: Additive endocannabinoid system modulation

   Clinical Pearls

  • More effective in rheumatoid arthritis, migraine, and mixed chronic pain than osteoarthritis
  • Lower doses paradoxically more effective than higher doses
  • Time-dependent benefit; patience required for full effect. 
  • Gender differences: EPA/DHA more effective in men; AA reduction more relevant in women
  • Consider baseline omega-6:omega-3 ratio; higher ratios predict better response

—

9. PALMITOYLETHANOLAMIDE (PEA)

   Level of Evidence

      Grade A: Multiple systematic reviews and meta-analyses, numerous double-blind RCTs; high-quality evidence

   Primary Indications

  1. Broad-spectrum chronic pain: nociceptive, neuropathic, and nociplastic
  2. Diabetic neuropathy
  3. Chemotherapy-induced peripheral neuropathy
  4. Low back pain (with radicular component)
  5. Fibromyalgia
  6. Osteoarthritis
  7. Carpal tunnel syndrome
  8. Chronic pelvic pain
  9. Temporomandibular disorders

   Mechanisms of Action

  • Endocannabinoid system modulation: Indirect CB1/CB2 receptor activation via “entourage effect”
  • Mast cell stabilization: Reduces degranulation and histamine release
  • Glial cell modulation: Controls microglial and astrocyte activation
  • PPAR-α agonism: Anti-inflammatory and neuroprotective signaling
  • Central and peripheral sensitization reduction: Decreases wind-up ratio, allodynia, and hyperalgesia
  • 6Pain modulation enhancement: Improves conditioned pain modulation (descending inhibition)

   Recommended Dosing

  • Standard dose: 300-600 mg twice daily (600-1200 mg/day total)
  • Micronized PEA: 300-600 mg twice daily
  • Ultramicronized PEA (um-PEA): 300-600 mg twice daily (preferred formulation)
  • Co-ultramicronized PEA (with quercetin or luteolin): 350-700 mg twice daily
  • Duration: Minimum 4-6 weeks for initial benefit; optimal effects at 8-12 weeks
  • Timing: Can be taken with or without food

   Formulation Considerations

      Critical: Particle size dramatically affects bioavailability and efficacy

  • Ultramicronized formulations (particle size 10 µm) cross blood-brain barrier and blood-spinal cord barrier effectively
  • Micronized superior to naïve PEA
  • Co-ultramicronized with flavonoids (quercetin, luteolin) may enhance efficacy via synergistic mechanisms

   Estimated Cost

  • Micronized PEA: $30-50/month
  • Ultramicronized PEA: $40-70/month
  • Co-ultramicronized formulations: $50-80/month

   Safety Profile – Excellent safety and tolerability

  • No serious adverse events in any clinical trial
  • Minimal side effects (rare mild GI upset)
  • No drug interactions reported
  • No tolerance development
  • Safe for long-term use (studied up to 12+ months)
  • No psychoactive effects (not a direct cannabinoid)

Synergistic Combinations

  1. Quercetin or luteolin: Enhanced anti-inflammatory effects (co-ultramicronized formulations)
  2. Curcumin: Complementary neuroinflammation modulation
  3. Omega-3 fatty acids: Additive SPM production
  4. Opioids: Reduces opioid tolerance and side effects; opioid-sparing

Clinical Pearls

  • Opioid-sparing effects: Can reduce opioid requirements and prevent tolerance development
  • Effective across all pain types (nociceptive, neuropathic, nociplastic)
  • Benefits observable within 4 weeks; maximal at 8-12 weeks
  • Ultramicronized formulation essential for CNS penetration. 
  • Particularly effective as adjunct to standard analgesics
  • May be superior to placebo with SMD of -1.68 (95% CI 1.05-2.31)

—

10. RESVERATROL

   Level of Evidence

      Grade B-C: Extensive preclinical evidence; limited clinical trials in pain; moderate-quality evidence

   Primary Indications

  1. Inflammatory pain
  2. Osteoarthritis
  3. Neuropathic pain (preclinical evidence)
  4. Central sensitization states
  5. Chronic inflammatory conditions

   Mechanisms of Action

  1. COX-2 inhibition: Prevents COX-2 mRNA increase; prolonged antinociceptive effect related to COX-2 expression impairment
  2. NF-κB suppression: Reduces pro-inflammatory cytokine production
  3. SIRT1 activation: Enhances mitochondrial biogenesis and cellular stress resistance
  4. Nrf2 activation: Upregulates endogenous antioxidant systems
  5. MAPK pathway modulation: Reduces inflammatory signaling (PI3K/Akt/mTOR, TNFR1/NF-κB)
  6. Microglial modulation: Attenuates spinal microglia activation
  7. Ion channel regulation: Inhibits voltage-gated ion channels involved in pain transmission

   Recommended Dosing

  • Chronic pain: 150-500 mg/day
  • Osteoarthritis: 250-500 mg/day
  • Anti-inflammatory effects: 100-250 mg/day
  • Duration: Minimum 8-12 weeks
  • Timing: Take with meals containing fat to enhance absorption

   Formulation Considerations

  • Trans-resveratrol preferred (more bioactive form)
  • Micronized formulations improve bioavailability
  • Poor native bioavailability; enhanced formulations recommended
  • Combination with piperine may enhance absorption

   Estimated Cost

  • Standard resveratrol: $20-40/month
  • Enhanced bioavailability formulations: $35-60/month

   Safety Profile – Good safety

  • Well-tolerated at doses up to 5 g/day in short-term studies
  • GI upset at high doses
  • Theoretical antiplatelet effects; caution with anticoagulants
  • No serious adverse events in clinical trials

   Synergistic Combinations

  1. Omega-3 fatty acids: Synergistic mitochondrial and anti-inflammatory effects
  2. Curcumin: Complementary NF-κB inhibition
  3. Quercetin: Enhanced antioxidant and anti-inflammatory activity
  4. CoQ10: Additive mitochondrial support

   Clinical Pearls

  • Prolonged antinociceptive effect: single injection produces sustained analgesia in animal models
  • Prevents bilateralization of COX-2 expression (may prevent chronic pain development)
  • Extensive preclinical evidence; clinical trials in pain are limited
  • May be particularly useful for osteoarthritis given anti-inflammatory and chondroprotective effects
  • Bioavailability remains a significant challenge; enhanced formulations recommended

—

References 1-25 (Nutraceuticals 1-10):

  1. Acetyl-L-Carnitine for the Treatment of Diabetic Peripheral Neuropathy. Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. The Cochrane Database of Systematic Reviews. 2019;6:CD011265. doi:10.1002/14651858.CD011265.pub2.
  2. Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathic Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Li S, Li Q, Li Y, et al. PloS One. 2015;10(3):e0119479. doi:10.1371/journal.pone.0119479.
  3. Acetyl-L-Carnitine in Chronic Pain: A Narrative Review. Sarzi-Puttini P, Giorgi V, Di Lascio S, Fornasari D. Pharmacological Research. 2021;173:105874. doi:10.1016/j.phrs.2021.105874.
  4. Analgesia Induced by the Epigenetic Drug, L-Acetylcarnitine, Outlasts the End of Treatment in Mouse Models of Chronic Inflammatory and Neuropathic Pain. Notartomaso S, Mascio G, Bernabucci M, et al. Molecular Pain. 2017;13:1744806917697009. doi:10.1177/1744806917697009.
  5. Effectiveness of Boswellia and Boswellia Extract for Osteoarthritis Patients: A Systematic Review and Meta-Analysis. Yu G, Xiang W, Zhang T, et al. BMC Complementary Medicine and Therapies. 2020;20(1):225. doi:10.1186/s12906-020-02985-6.
  6. Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study. Jayaram M, Kim J, Baek KS, et al. Journal of Medicinal Food. 2025;. doi:10.1177/1096620X251392467.
  7. Efficacy and Safety of Boswellia Serrata and Apium Graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial. Vaidya N, Agarwal R, Dipankar DG, et al. Pharmaceutical Research. 2025;42(2):249-269. doi:10.1007/s11095-025-03818-2.
  8. Efficacy and Safety of Magnesium for the Management of Chronic Pain in Adults: A Systematic Review. Park R, Ho AM, Pickering G, et al. Anesthesia and Analgesia. 2020;131(3):764-775. doi:10.1213/ANE.0000000000004673.
  9. Management of Headache (2023). Jane Abanes PhD DNP MSN/Ed PMHCNS PMHNP-BC RN, Natasha M. Antonovich PharmD BCPS, Andrew C. Buelt DO, et al. Department of Veterans Affairs.
  10. Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review. von Luckner A, Riederer F. Headache. 2018;58(2):199-209. doi:10.1111/head.13217.
  11. Magnesium in Pain Research: State of the Art. Srebro D, Vuckovic S, Milovanovic A, et al. Current Medicinal Chemistry. 2017;24(4):424-434. doi:10.2174/0929867323666161213101744.
  12. Serum Magnesium Levels and Their Association With Sleep Quality and Disease Severity in Fibromyalgia Syndrome: An Observational Cross-Sectional Study. Alisik T, Reis Altan YC, Olkay SG, Sahingoz Bakirci E. Medicine. 2025;104(29):e43446. doi:10.1097/MD.0000000000043446.
  13. A Standardized Boswellia Serrata Extract Shows Improvements in Knee Osteoarthritis Within Five Days-a Double-Blind, Randomized, Three-Arm, Parallel-Group, Multi-Center, Placebo-Controlled Trial. Majeed A, Majeed S, Satish G, et al. Frontiers in Pharmacology. 2024;15:1428440. doi:10.3389/fphar.2024.1428440.
  14. Oral Herbal Therapies for Treating Osteoarthritis. Cameron M, Chrubasik S. The Cochrane Database of Systematic Reviews. 2014;(5):CD002947. doi:10.1002/14651858.CD002947.pub2.
  15. N-Acetyl-Cysteine Attenuates Neuropathic Pain by Suppressing Matrix Metalloproteinases. Li J, Xu L, Deng X, et al. Pain. 2016;157(8):1711-1723. doi:10.1097/j.pain.0000000000000575.
  16. Efficacy and Safety of N-Acetylcysteine for the Management of Chronic Pain in Adults: A Systematic Review and Meta-Analysis. Mohiuddin M, Pivetta B, Gilron I, Khan JS. Pain Medicine (Malden, Mass.). 2021;22(12):2896-2907. doi:10.1093/pm/pnab042.
  17. N-Acetyl-Cysteine Causes Analgesia by Reinforcing the Endogenous Activation of Type-2 Metabotropic Glutamate Receptors. Bernabucci M, Notartomaso S, Zappulla C, et al. Molecular Pain. 2012;8:77. doi:10.1186/1744-8069-8-77.
  18. N-Acetyl-Cysteine, a Drug That Enhances the Endogenous Activation of Group-Ii Metabotropic Glutamate Receptors, Inhibits Nociceptive Transmission in Humans. Truini A, Piroso S, Pasquale E, et al. Molecular Pain. 2015;11:14. doi:10.1186/s12990-015-0009-2.
  19. Topical Combination of Meldonium and N-Acetyl Cysteine Relieves Allodynia in Rat Models of CRPS-1 and Peripheral Neuropathic Pain by Enhancing NO-mediated Tissue Oxygenation. Fulas OA, Laferriere A, Stein RS, Bohle DS, Coderre TJ. Journal of Neurochemistry. 2020;152(5):570-584. doi:10.1111/jnc.14943.
  20. The Role of Diet and Non-Pharmacologic Supplements in the Treatment of Chronic Neuropathic Pain: A Systematic Review. Frediani JK, Lal AA, Kim E, et al. Pain Practice : The Official Journal of World Institute of Pain. 2024;24(1):186-210. doi:10.1111/papr.13291.
  21. Deciphering Resveratrol’s Role in Modulating Pathological Pain: From Molecular Mechanisms to Clinical Relevance. Wang B, Jiang HM, Qi LM, et al. Phytotherapy Research : PTR. 2024;38(1):59-73. doi:10.1002/ptr.8021.
  22. Analgesic and Anti-Inflammatory Activities of Resveratrol Through Classic Models in Mice and Rats. Wang G, Hu Z, Song X, et al. Evidence-Based Complementary and Alternative Medicine : eCAM. 2017;2017:5197567. doi:10.1155/2017/5197567.
  23. Antinociceptive Effect of Resveratrol in Carrageenan-Evoked Hyperalgesia in Rats: Prolonged Effect Related to COX-2 Expression Impairment. Pham-Marcou TA, Beloeil H, Sun X, et al. Pain. 2008;140(2):274-283. doi:10.1016/j.pain.2008.08.010.
  24. The Role and Current Research Status of Resveratrol in the Treatment of Osteoarthritis and Its Mechanisms: A Narrative Review. Zou X, Xu H, Qian W. Drug Metabolism Reviews. 2024;56(4):399-412. doi:10.1080/03602532.2024.2402751. 
  25. Resveratrol: Harnessing Nature’s Potential for Chronic Pain Relief. Wu H, Wu JY, Gao SJ, et al. Aging and Disease. 2025;:AD.2025.0530. doi:10.14336/AD.2025.0530.

SUMMARY AND CLINICAL INTEGRATION

Evidence Hierarchy for Chronic Pain Nutraceuticals

Based on evidence reviewed 3/22/26:

Grade A (High-quality evidence – mixed conclusions):

  1. Palmitoylethanolamide (PEA)
  2. Omega-3 fatty acids (EPA/DHA)

Grade A-B (Moderate-to-high quality evidence):

  1. Curcumin: An umbrella meta-analysis of 11 meta-analyses confirmed significant reductions in VAS and WOMAC scores for osteoarthritis. VA/DoD guidelines note positive effects compared to placebo.[5][6]
  2. Boswellia serrata:  A Cochrane review found high-quality evidence for enriched Boswellia extract improving pain and function in OA, with NNTB of 2-4. Multiple recent RCTs confirm efficacy.[9][10][11]
  3. Omega-3 fatty acids: A 2025 meta-analysis of 41 RCTs showed moderate pain reduction (SMD -0.55), but the large VITAL trial (n=25,871) found no effect on pain prevalence or severity with standard dosing. Benefits appear condition-specific (rheumatoid arthritis, migraine) rather than universal.[3][4]

Grade B (Moderate-quality evidence):

  1. Alpha-lipoic acid: A 2024 Cochrane review concluded ALA “probably has little or no effect on neuropathy symptoms” at 6 months (moderate-certainty evidence). The SYDNEY 2 trial showed benefit at 600 mg/day, but long-term evidence is limited.[7][8]
  2. CoQ10: Evidence is limited primarily to fibromyalgia, with small studies (n=20-22) showing benefit. Should remain Grade B or possibly B-C.[12][13]
  3. Magnesium (for migraine): AAN guidelines classify it as “probably effective” (Level B), and umbrella reviews confirm strong GRADE evidence for reducing migraine frequency/intensity.[14][15]
  4. Melatonin: Evidence is mixed. A 2020 meta-analysis showed benefit for chronic pain (SMD -0.65), but a 2025 RCT found no benefit for neuropathic pain. Grade B-C may be more appropriate.[16][17]
  5. Palmitoylethanolamide (PEA):  While meta-analyses show efficacy (SMD -0.9 to -1.16 for pain reduction), a 2022 Cochrane-style systematic review noted high heterogeneity (I² = 99%) and publication bias, with only two high-quality RCTs available. The evidence is promising but not yet “high-quality.”[1][2]
  6. Acetyl-L-carnitine: A Cochrane review found “very uncertain” evidence for pain reduction in DPN, though a 2024 phase 3 trial in China showed significant improvement in neuropathy scores.[18][19]

Grade B-C (Emerging evidence):

  1. NAD+ precursors
  2. Vitamin D3
  3. Quercetin
  4. N-acetyl cysteine
  5. Resveratrol
  6. Sulforaphane
  7. Taurine

Based on evidence reviewed 3/22/26:

Hierarchy:

Grade

Nutraceuticals

Rationale

References

A-B (Moderate-to-High)

Curcumin (bioavailable forms), Boswellia serrata, Magnesium (migraine)

Multiple meta-analyses, guideline support

[1], [2], [3], [4], [5]

B (Moderate)

PEA, Omega-3 (condition-specific), Alpha-lipoic acid (600 mg/day), Acetyl-L-carnitine

Positive meta-analyses but heterogeneity, conflicting large trials

[6], [7], [8], [9], [10], [11]

B-C (Limited/Emerging)

CoQ10, Melatonin, Vitamin D3, NAD+ precursors, Quercetin, Resveratrol, N-acetyl cysteine, Sulforaphane, Taurine

Small studies, mixed results, or limited human data

[12], [13], [14], [15]

References

  1. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
  2. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.
  3. Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
  4. The Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Pain Prevalence and Severity in Older Adults: A Large-Scale Ancillary Study of the VITamin D and OmegA-3 triaL (VITAL). Soens MA, Sesso HD, Manson JE, et al. Pain. 2024;165(3):635-643. doi:10.1097/j.pain.0000000000003044.
  5. The Efficacy of Curcumin in Relieving Osteoarthritis: A Meta-Analysis of Meta-Analyses. Bideshki MV, Jourabchi-Ghadim N, Radkhah N, et al. Phytotherapy Research : PTR. 2024;38(6):2875-2891. doi:10.1002/ptr.8153.
  6. The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
  7. Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. The Cochrane Database of Systematic Reviews. 2024;1:CD012967. doi:10.1002/14651858.CD012967.pub2.
  8. Oral Treatment With Alpha-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 Trial. Ziegler D, Ametov A, Barinov A, et al. Diabetes Care. 2006;29(11):2365-70. doi:10.2337/dc06-1216.
  9. Oral Herbal Therapies for Treating Osteoarthritis. Cameron M, Chrubasik S. The Cochrane Database of Systematic Reviews. 2014;(5):CD002947. doi:10.1002/14651858.CD002947.pub2.
  10. Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study. Jayaram M, Kim J, Baek KS, et al. Journal of Medicinal Food. 2025;. doi:10.1177/1096620X251392467.
  11. A Standardized Boswellia Serrata Extract Shows Improvements in Knee Osteoarthritis Within Five Days-a Double-Blind, Randomized, Three-Arm, Parallel-Group, Multi-Center, Placebo-Controlled Trial. Majeed A, Majeed S, Satish G, et al. Frontiers in Pharmacology. 2024;15:1428440. doi:10.3389/fphar.2024.1428440.
  12. Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?. Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Antioxidants & Redox Signaling. 2013;19(12):1356-61. doi:10.1089/ars.2013.5260.
  13. Role for a Water-Soluble Form of CoQ10 in Female Subjects Affected by Fibromyalgia. A Preliminary Study. Di Pierro F, Rossi A, Consensi A, Giacomelli C, Bazzichi L. Clinical and Experimental Rheumatology. 2017 May-Jun;35 Suppl 105(3):20-27.
  14. Evidence-Based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Holland S, Silberstein SD, Freitag F, et al. Neurology. 2012;78(17):1346-53. doi:10.1212/WNL.0b013e3182535d0c.
  15. Magnesium and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational and Intervention Studies. Veronese N, Demurtas J, Pesolillo G, et al. European Journal of Nutrition. 2020;59(1):263-272. doi:10.1007/s00394-019-01905-w.
  16. Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
  17. Melatonin for Neuropathic Pain: A Double-Blind, Placebo-Controlled, Randomized, Crossover Trial. Gilron I, Elkerdawy H, Tu D, et al. Pain. 2025;:00006396-990000000-00905. doi:10.1097/j.pain.0000000000003651.
  18. Acetyl-L-Carnitine for the Treatment of Diabetic Peripheral Neuropathy. Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. The Cochrane Database of Systematic Reviews. 2019;6:CD011265. doi:10.1002/14651858.CD011265.pub2.
  19. Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. Guo L, Pan Q, Cheng Z, et al. Diabetes. 2024;73(5):797-805. doi:10.2337/db23-0377.
  20. Acetyl-L-Carnitine in Painful Peripheral Neuropathy: A Systematic Review. Di Stefano G, Di Lionardo A, Galosi E, Truini A, Cruccu G. Journal of Pain Research. 2019;12:1341-1351. doi:10.2147/JPR.S190231.

 

 

 

Suggested Combination Protocols by Pain Type

   Neuropathic Pain:

  1. First-line: Alpha-lipoic acid (600 mg/day) + Acetyl-L-carnitine (2000-3000 mg/day)
  2. Add: PEA (ultramicronized, 600 mg BID) + Omega-3 (1-1.35 g EPA+DHA/day)
  3. Consider: NAD+ precursors (NR 500 mg/day), Taurine (1500-3000 mg/day)

   Inflammatory/Osteoarthritis Pain:

  1. First-line: Curcumin (enhanced bioavailability, 500-1000 mg/day) + Boswellia (100-400 mg standardized extract/day)
  2. Add: Omega-3 (1-1.35 g EPA+DHA/day) + Quercetin (500-1000 mg/day)- Consider: Resveratrol (250-500 mg/day)

   Fibromyalgia/Central Sensitization:

  1. First-line: PEA (ultramicronized, 600 mg BID) + CoQ10 (300 mg/day)
  2. Add: Magnesium (400-600 mg/day) + Melatonin (3-5 mg at bedtime)
  3. Consider: Omega-3, Vitamin D (if deficient)

   Migraine Prophylaxis:

  • First-line: Magnesium (400-600 mg/day) + CoQ10 (300 mg/day)
  • Add: Omega-3 (1-1.35 g EPA+DHA/day) + Melatonin (3 mg at bedtime)
  • Consider: Riboflavin (B2, 400 mg/day)

   Chemotherapy-Induced Neuropathy:

  1. First-line: Alpha-lipoic acid (600-1200 mg/day) + Acetyl-L-carnitine (2000-3000 mg/day)
  2. Add: NAD+ precursors (NR 500-1000 mg/day)
  3. Consider: PEA, Omega-3

—

General Principles for Clinical Integration

  •    Start with one or two agents; add sequentially to assess individual response
  •    Allow adequate time for therapeutic effect (typically 8-12 weeks minimum)
  •    Use enhanced bioavailability formulations:
    1. Curcumin
    2. PEA
    3. Quercetin,
    4. Resveratrol
  •    Consider underlying pathophysiology when selecting agents:
    1. Neuroinflammation → Curcumin, PEA, Sulforaphane
    2. Oxidative Stress → Alpha-lipoic acid, NAC, Resveratrol
    3. Mitochondrial Dysfunction → CoQ10, NAD+ precursors, Alpha-lipoic acid-
    4. Central Sensitization → PEA, Omega-3, Magnesium
  •    Combine agents with complementary mechanisms for synergistic effects

 

—

References

  1. Resveratrol: Harnessing Nature’s Potential for Chronic Pain Relief. Wu H, Wu JY, Gao SJ, et al. Aging and Disease. 2025;:AD.2025.0530. doi:10.14336/AD.2025.0530.
  2. Nicotinamide Riboside Relieves Paclitaxel-Induced Peripheral Neuropathy and Enhances Suppression of Tumor Growth in Tumor-Bearing Rats. Hamity MV, White SR, Blum C, Gibson-Corley KN, Hammond DL. Pain. 2020;161(10):2364-2375. doi:10.1097/j.pain.0000000000001924.
  3. Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Trammell SA, Weidemann BJ, Chadda A, et al. Scientific Reports. 2016;6:26933. doi:10.1038/srep26933.
  4. Nicotinamide Riboside, a Form of Vitamin B3 and NAD+ Precursor, Relieves the Nociceptive and Aversive Dimensions of Paclitaxel-Induced Peripheral Neuropathy in Female Rats. Hamity MV, White SR, Walder RY, et al. Pain. 2017;158(5):962-972. doi:10.1097/j.pain.0000000000000862.
  5. Restoration of Mitochondrial Function Alleviates Trigeminal Neuropathic Pain in Mice. Yang J, Xie S, Guo J, et al. Free Radical Biology & Medicine. 2025;226:185-198. doi:10.1016/j.freeradbiomed.2024.11.011.
  6. Preclinical and Clinical Evidence of NAD Precursors in Health, Disease, and Ageing. Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Mechanisms of Ageing and Development. 2021;199:111567. doi:10.1016/j.mad.2021.111567.
  7. NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Yaku K, Nakagawa T. Antioxidants & Redox Signaling. 2023;39(16-18):1133-1149. doi:10.1089/ars.2023.0354.
  8. Vitamin D for the Treatment of Chronic Painful Conditions in Adults. Straube S, Derry S, Straube C, Moore RA. The Cochrane Database of Systematic Reviews. 2015;(5):CD007771. doi:10.1002/14651858.CD007771.pub3.
  9. The Effect of Vitamin D Supplementation on Pain: An Analysis of Data From the D-Health Randomised Controlled Trial. Rahman A, Waterhouse M, Baxter C, et al. The British Journal of Nutrition. 2023;130(4):633-640. doi:10.1017/S0007114522003567.
  10. Effect of Vitamin D Supplementation on Pain: A Systematic Review and Meta-Analysis. Wu Z, Malihi Z, Stewart AW, Lawes CM, Scragg R. Pain Physician. 2016 Sep-Oct;19(7):415-27.
  11. Monthly Vitamin D Supplementation, Pain, and Pattern of Analgesic Prescription: Secondary Analysis From the Randomized, Double-Blind, Placebo-Controlled Vitamin D Assessment Study. Wu Z, Camargo CA, Malihi Z, et al. Pain. 2018;159(6):1074-1082. doi:10.1097/j.pain.0000000000001189.
  12. Effect of Vitamin D Supplementation in Chronic Widespread Pain: A Systematic Review and Meta-Analysis. Yong WC, Sanguankeo A, Upala S. Clinical Rheumatology. 2017;36(12):2825-2833. doi:10.1007/s10067-017-3754-y.
  13. Cholecalciferol (Vitamin D) Reduces Rat Neuropathic Pain by Modulating Opioid Signaling. Poisbeau P, Aouad M, Gazzo G, et al. Molecular Neurobiology. 2019;56(10):7208-7221. doi:10.1007/s12035-019-1582-6.
  14. Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
  15. Analgesic Benefits of Pharmacological and Nonpharmacological Sleep Interventions for Adults With Fibromyalgia: A Systematic Review and Meta-Analyses. Abolhosseini S, Malatesta A, Asmundson AJN, Gilron I, Salomons TV. Pain. 2025;:00006396-990000000-00967. doi:10.1097/j.pain.0000000000003708.
  16. Exogenous Melatonin in the Treatment of Pain: A Systematic Review and Meta-Analysis. Zhu C, Xu Y, Duan Y, et al. Oncotarget. 2017;8(59):100582-100592. doi:10.18632/oncotarget.21504.
  17. Analgesic Effects of Melatonin: A Review of Current Evidence From Experimental and Clinical Studies. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I. Journal of Pineal Research. 2011;51(3):270-7. doi:10.1111/j.1600-079X.2011.00895.x.
  18. Melatonin Treatment Has Consistent but Transient Beneficial Effects on Sleep Measures and Pain in Patients With Severe Chronic Pain: The DREAM-CP Randomised Controlled Trial. Onyeakazi UM, Columb MO, Rosalind A, Kanakarajan S, Galley HF. British Journal of Anaesthesia. 2024;132(4):725-734. doi:10.1016/j.bja.2024.01.012.
  19. Adjuvant Use of Melatonin for Treatment of Fibromyalgia. Hussain SA, Al-Khalifa II, Jasim NA, Gorial FI. Journal of Pineal Research. 2011;50(3):267-71. doi:10.1111/j.1600-079X.2010.00836.x.
  20. Emerging Promise of Sulforaphane-Mediated Nrf2 Signaling Cascade Against Neurological Disorders. Uddin MS, Mamun AA, Jakaria M, et al. The Science of the Total Environment. 2020;707:135624. doi:10.1016/j.scitotenv.2019.135624.
  21. Treatment With Sulforaphane Produces Antinociception and Improves Morphine Effects During Inflammatory Pain in Mice. Redondo A, Chamorro PAF, Riego G, Leánez S, Pol O. The Journal of Pharmacology and Experimental Therapeutics. 2017;363(3):293-302. doi:10.1124/jpet.117.244376.
  22. Sulforaphane: An Emerging Star in Neuroprotection and Neurological Disease Prevention. Wu N, Luo Z, Deng R, et al. Biochemical Pharmacology. 2025;233:116797. doi:10.1016/j.bcp.2025.116797.
  23. Effects of Sulforaphane in the Central Nervous System. Huang C, Wu J, Chen D, et al. European Journal of Pharmacology. 2019;853:153-168. doi:10.1016/j.ejphar.2019.03.010.
  24. Broccoli for the Brain: A Review of the Neuroprotective Mechanisms of Sulforaphane. Bessetti RN, Litwa KA. Frontiers in Cellular Neuroscience. 2025;19:1601366. doi:10.3389/fncel.2025.1601366.
  25. Sulforaphane-Enriched Broccoli Sprouts Pretreated by Pulsed Electric Fields Reduces Neuroinflammation and Ameliorates Scopolamine-Induced Amnesia in Mouse Brain Through Its Antioxidant Ability via Nrf2-Ho-1 Activation. Subedi L, Cho K, Park YU, Choi HJ, Kim SY. Oxidative Medicine and Cellular Longevity. 2019;2019:3549274. doi:10.1155/2019/3549274.
  26. The Emerging Role of Quercetin in the Treatment of Chronic Pain. Liu C, Liu DQ, Tian YK, et al. Current Neuropharmacology. 2022;20(12):2346-2353. doi:10.2174/1570159X20666220812122437.
  27. Quercetin Alleviates Osteoarthritis Pain by Inhibiting Vascular Endothelial Growth Factor a Through Regulating cGAS/STING Pathway. Hu E, Wei Y, Liao T, et al. Journal of Cellular and Molecular Medicine. 2026;30(1):e70992. doi:10.1111/jcmm.70992.
  28. Advance in the Pharmacological Effects of Quercetin in Modulating Oxidative Stress and Inflammation Related Disorders. Zhou Y, Qian C, Tang Y, et al. Phytotherapy Research : PTR. 2023;37(11):4999-5016. doi:10.1002/ptr.7966.
  29. Quercetin Alleviates Rat Osteoarthritis by Inhibiting Inflammation and Apoptosis of Chondrocytes, Modulating Synovial Macrophages Polarization to M2 Macrophages. Hu Y, Gui Z, Zhou Y, et al. Free Radical Biology & Medicine. 2019;145:146-160. doi:10.1016/j.freeradbiomed.2019.09.024.
  30. Quercetin-Mediated SIRT1 Activation Attenuates Collagen-Induced Mice Arthritis. Shen P, Lin W, Ba X, et al. Journal of Ethnopharmacology. 2021;279:114213. doi:10.1016/j.jep.2021.114213.
  31. Molecular Docking of Quercetin: A Promising Approach for the Development of New Anti-Inflammatory and Analgesic Drugs. Ettitaou A, Kabdy H, Oubella K, et al. Natural Product Research. 2025;39(11):3202-3211. doi:10.1080/14786419.2024.2333053.
  32. Comparative Investigation of Analgesic Tolerance to Taurine, Sodium Salicylate and Morphine: Involvement of Peripheral Muscarinic Receptors. Akbari E, Beheshti F, Zarmehri HA, et al. Neuroscience Letters. 2023;795:137041. doi:10.1016/j.neulet.2022.137041.
  33. Taurine Protects Against Myelin Damage of Sciatic Nerve in Diabetic Peripheral Neuropathy Rats by Controlling Apoptosis of Schwann Cells via NGF/Akt/GSK3β Pathway. Li K, Shi X, Luo M, et al. Experimental Cell Research. 2019;383(2):111557. doi:10.1016/j.yexcr.2019.111557.
  34. Taurine Ameliorates Axonal Damage in Sciatic Nerve of Diabetic Rats and High Glucose Exposed DRG Neuron by PI3K/Akt/mTOR-dependent Pathway. Zhang M, Shi X, Luo M, et al. Amino Acids. 2021;53(3):395-406. doi:10.1007/s00726-021-02957-1.
  35. Antinociceptive Effect of Intrathecal Administration of Taurine in Rat Models of Neuropathic Pain. Terada T, Hara K, Haranishi Y, Sata T. Canadian Journal of Anaesthesia = Journal Canadien d’Anesthesie. 2011;58(7):630-637. doi:10.1007/s12630-011-9504-8.
  36. Taurine Replacement Attenuates Hyperalgesia and Abnormal Calcium Signaling in Sensory Neurons of STZ-D Rats. Li F, Obrosova IG, Abatan O, et al. American Journal of Physiology. Endocrinology and Metabolism. 2005;288(1):E29-36. doi:10.1152/ajpendo.00168.2004.
  37. Neuropsychopharmacological Actions of Taurine. Banerjee SP, Ragnauth A, Chan CY, et al. Advances in Experimental Medicine and Biology. 2013;775:3-18. doi:10.1007/978-1-4614-6130-2_1.

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

 

 

.